MedTrace Logo

ctDNA for Risk Stratification in Melanoma

NCT07531121 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 296

Last updated 2026-04-15

No results posted yet for this study

Summary

This study examines circulating tumor DNA (ctDNA) as a biomarker in patients with primary melanoma, prior to surgical excision. The hypothesis is that ctDNA may be detectable in pre-operative blood samples from patients with high-risk primary melanoma, potentially providing a baseline measurement for future disease monitoring.

Conditions

  • Melanoma (Skin Cancer)

Sponsors & Collaborators

  • Danish Cancer Society

    collaborator OTHER

  • Danish Cancer Research Foundation

    collaborator OTHER

  • DCCC ctDNA Research Center

    collaborator UNKNOWN

  • CAG in Cancer immunotherapy

    collaborator UNKNOWN

  • Herlev and Gentofte Hospital

    lead OTHER

Principal Investigators

  • Lisbet R Hölmich, MD, DMSc, Professor · Dept. of Plastic and Reconstructive Surgery, Herlev and Gentofte University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-10
Primary Completion
2025-05-20
Completion
2026-05-03

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07531121 on ClinicalTrials.gov